Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy -- Ignore unavailable to you. Want to Upgrade?

To: Michael Cash who wrote (121)	12/30/1998 11:41:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 370

The "flesh-eater" is Gram-positive (Salmonella is Gram-negative), so I don't know if it would selectively home to a tumor. Lots of other reasons that you wouldn't want to do this, and that the FDA would kick you in the butt for even thinking about it. The question, however, is rational when framed in the original irrational VION frame. The trend is clearly to use an innocuous bug to deliver something that is tumor-selective, a prodrug for example. See the abtract linked from my previous post.